IL314357A - Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment - Google Patents

Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment

Info

Publication number
IL314357A
IL314357A IL314357A IL31435724A IL314357A IL 314357 A IL314357 A IL 314357A IL 314357 A IL314357 A IL 314357A IL 31435724 A IL31435724 A IL 31435724A IL 314357 A IL314357 A IL 314357A
Authority
IL
Israel
Prior art keywords
nucleic acid
viral vector
seq
viral
cancer
Prior art date
Application number
IL314357A
Other languages
English (en)
Hebrew (he)
Inventor
COTUGNO Gabriella
Scarselli Elisa
Morena D'ALISE Anna
Lahm Armin
LEONI Guido
Original Assignee
Nouscom Ag
COTUGNO Gabriella
Scarselli Elisa
Anna Morena Dalise
Lahm Armin
LEONI Guido
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nouscom Ag, COTUGNO Gabriella, Scarselli Elisa, Anna Morena Dalise, Lahm Armin, LEONI Guido filed Critical Nouscom Ag
Publication of IL314357A publication Critical patent/IL314357A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL314357A 2022-01-17 2023-01-17 Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment IL314357A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22151830 2022-01-17
PCT/EP2023/050917 WO2023135313A1 (en) 2022-01-17 2023-01-17 Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment

Publications (1)

Publication Number Publication Date
IL314357A true IL314357A (en) 2024-09-01

Family

ID=80222249

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314357A IL314357A (en) 2022-01-17 2023-01-17 Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment

Country Status (10)

Country Link
US (1) US20250115928A1 (enExample)
EP (1) EP4466286A1 (enExample)
JP (1) JP2025503721A (enExample)
KR (1) KR20240134204A (enExample)
CN (1) CN118556081A (enExample)
AU (1) AU2023207821A1 (enExample)
CA (1) CA3248326A1 (enExample)
IL (1) IL314357A (enExample)
MX (1) MX2024008847A (enExample)
WO (1) WO2023135313A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2415783B1 (en) * 2006-10-16 2016-12-14 Genelux Corporation Modified vaccinia virus strains for use in a diagnostic and therapeutic method
US8394385B2 (en) * 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
SG11202006457YA (en) * 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
CN113454231A (zh) * 2018-12-21 2021-09-28 渥太华医院研究所 修饰的正痘病毒载体

Also Published As

Publication number Publication date
EP4466286A1 (en) 2024-11-27
AU2023207821A1 (en) 2024-09-05
MX2024008847A (es) 2024-07-25
KR20240134204A (ko) 2024-09-06
CA3248326A1 (en) 2023-07-20
CN118556081A (zh) 2024-08-27
WO2023135313A1 (en) 2023-07-20
JP2025503721A (ja) 2025-02-04
US20250115928A1 (en) 2025-04-10

Similar Documents

Publication Publication Date Title
KR102351555B1 (ko) Hpv 및 관련 질환용 면역 증강 치료 백신
BR112021012078A2 (pt) Vetores de ortopoxvírus modificados
JP2011504105A (ja) ポックスウイルス腫瘍細胞崩壊性ベクター
US12357672B2 (en) Protein molecule of interleukins 12a and b combined with additional factors
US12544433B2 (en) Melanoma canine vaccine compositions and methods of use thereof
BR112012033363B1 (pt) Vetor de expressão e composição farmacêutica
EP4452299A1 (en) Immunostimulatory mrna compositions and uses thereof
EP3824097A1 (en) Major histocompatibility complex class ii-expressing cancer cell vaccine and methods of use for producing integrated immune responses
JP2025522951A (ja) 腫瘍溶解性ワクシニアウイルスおよび組換えウイルスならびにその使用方法
US20250115928A1 (en) Recombinant Orthopox Viral Vector Encoding Immunostimulatory Proteins for Cancer Treatment
JP7211815B2 (ja) 抗腫瘍性組成物
CN110267671A (zh) 用于治疗癌细胞的组合物及其方法
CN114650838A (zh) 肿瘤特异性多肽序列及其应用
TW202317172A (zh) Tnfsf-l融合蛋白及其用途
CN116083435A (zh) 以人源light截短型突变蛋白为基础的抗肿瘤的应用
CN111603553A (zh) 一种靶向免疫系统治疗肿瘤的dna药物及其应用
CN116621966B (zh) 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用
HK40122972A (en) Nucleic acids encoding tgf-beta inhibitor and il-12 and uses thereof
TW202430647A (zh) 編碼TGF-β抑制劑及IL-12之核酸及其用途
HK40114150A (en) Immunostimulatory mrna compositions and uses thereof
WO2025157196A1 (zh) 经修饰的痘苗病毒及其用途
AU2024353556A1 (en) Interleukin 15 variant
HK40128394A (zh) CD47/SIRP-α免疫检查点抑制剂的组合物及其用途
HK40104197A (en) Tnfsf-l fusion proteins and uses thereof
HK40078961A (en) Irf modulator-expressing oncolytic viruses for treating cancer